10:06 AM EDT, 04/26/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) has been notified that the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending the approval of fruquintinib to treat adults with previously treated metastatic colorectal cancer, Takeda's partner Hutchmed ( HCM ) said Friday.

The European Commission -- the EU's executive arm -- will take into account the committee's recommendation when deciding about a potential marketing authorization for the drug in the EU, Norway, Liechtenstein and Iceland, Hutchmed ( HCM ) said

Takeda has an exclusive license to develop, sell, and make fruquintinib outside China, Hong Kong and Macau, Hutchmed ( HCM ) said.

Price: 13.06, Change: -0.02, Percent Change: -0.11